Cambrex plans to invest US$50 million to expand new mid-scale and large-scale API manufacturing capacity. The site will be located in Iowa, US.
The large scale API manufacturing capacity will be constructed with an area covering 45-acre land space. This new capacity will support the development and production of small molecule drug substances.
The expansion features an addition of 3 large-scale manufacturing work centers and 1 mid-scale work center to the facility in Iowa by significantly enhancing the site’s overall capacity to 30 per cent.
This expansion would be the sixth major expansion of the company in the past eight years.
The API manufacturing capacity all set to open in early 2022 will meet the customer needs. Once the expansion is done it is expected to provide job opportunities for 400 new employees.